The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
about
The Vpr protein from HIV-1: distinct roles along the viral life cycleHuman immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: implications for priming of HIV-1 reverse transcription.Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infectionThe HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repairHIV-1 nuclear import: matrix protein is back on center stage, this time together with VprHIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycleHuman immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzymeAntioxidant protection from HIV-1 gp120-induced neuroglial toxicityIdentification of the 15FRFG domain in HIV-1 Gag p6 essential for Vpr packaging into the virionNMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein VprSolution structure of human immunodeficiency virus type 1 Vpr(13-33) peptide in micellesSmall heat shock protein suppression of Vpr-induced cytoskeletal defects in budding yeast.Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signalingHuman immunodeficiency virus type 1 (HIV-1) Vpr-regulated cell death: insights into mechanismRoles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactionsInfluence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies.Pathogenesis of HIV-1 infection within bone marrow cells.Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicitySelective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndromeThe putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cellsFunctional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.Activation of transcription factors NF-kappaB and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expressionThe interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate.Genetic variation and HIV-associated neurologic disease.A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm)Vpr-host interactions during HIV-1 viral life cycle.Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisPhages and HIV-1: from display to interplay.Novel factors interfering with human immunodeficiency virus-type 1 replication in vivo and in vitro.Reducing plasma HIV RNA improves muscle amino acid metabolism.The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor.HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic interventionExpression and cytokine regulation of glucocorticoid receptors in Kaposi's sarcoma.The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor.A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particlesMutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr.Vpr of simian immunodeficiency virus of African green monkeys is required for replication in macaque macrophages and lymphocytes.Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.
P2860
Q21245211-7F094E4A-85AE-4695-BA23-9965741B8AA6Q24523263-A6292A2F-0085-4239-82E2-80B15E2F9BEEQ24531350-BBEEF264-5BA1-45DD-8BFC-93D325A2C4BEQ24629787-D4B02E92-C032-4715-9702-E05D7BC6DF06Q24653439-4FF28AAB-80EA-4EEF-A03C-9E426B708C77Q24654217-C350CF15-3EB4-49BA-A6E3-DDDFEAF7EAD7Q24682903-CCD31049-991F-4951-84E7-D086B19493D2Q24684302-8561AC08-FB14-4854-BD99-5C169A48D836Q24794513-BF7AFD71-A3BE-46D1-8394-5668192BE8A7Q24797248-203AA025-F63F-4BDB-9022-F46B65FA6DCFQ27620380-3A8D4531-54F1-47A4-B401-39A94075001DQ27629358-78389BF4-9C6A-4689-906F-C5861670112EQ27934278-C58820E0-A44B-428A-A799-CA38A407ABD4Q28202387-1F444303-1EE0-4847-8B61-6395C4EA37D5Q28245301-B418BB79-C12B-4CE9-A041-0952E7E88A0DQ28286819-6E972E27-868F-4FAB-BEE3-EF8AB5F45043Q30453160-FC65856A-6EF6-44B2-9D24-59122B19369DQ33334766-B1B1AA1F-5555-4A72-8FDA-32026565DBDBQ33705274-CE9CE446-9E94-4C69-8F70-E490587DF563Q33752757-0765BB32-028F-49E4-86B1-0CD00D16B51FQ33782776-29896963-2E80-431E-9249-A52FA60ED81FQ33787316-DEDE0B75-2653-48CE-99AC-B4853C8E1B52Q33804558-D7CA9C3D-A540-4C6B-A951-C9C0A9D59CA4Q33808996-DA6CAFE3-76AF-41E9-BD1E-631AD68FBCC1Q33819189-192EC3AF-6A99-4718-A3C9-E34A07E80F87Q33824939-79B7590D-C31C-456F-AE6A-C5683072B82FQ33828332-B77492A9-7909-4486-B3D2-3C8E510E7D2FQ34010283-28E30235-3D80-47F5-84B9-7AE8DF2170D1Q34273397-24E2233E-0387-46B5-B3DB-08D3DE9838EBQ34323296-233749D3-144F-454A-AE4B-6AD1B04BA4D6Q34550863-A6D6A422-5178-431F-A468-0DE0F9CA5A8DQ34647751-278D7DA9-9B80-441E-BF9D-15ECF50188B3Q34957142-AD8935BB-BDEB-41D5-ADC0-C56CC5D526E8Q35773933-4E13707C-F7ED-450D-8381-81437A8C91B6Q35834594-50F6C601-794E-487B-8A77-DE1E699A4411Q35850368-4DF9C6BC-8540-4F98-9420-A5D47A1F4D4BQ35850945-77E9A5CC-1961-4A83-8080-01864D4DA0D9Q35853370-7F34439A-CB05-4BCD-879A-A2951A47E448Q35888756-E6BD7DE5-946C-4215-B044-A66C1655AACEQ35890940-6470762B-A6D6-49DD-BF47-7CA0A0C15CE8
P2860
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@ast
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@en
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@nl
type
label
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@ast
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@en
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@nl
prefLabel
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@ast
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@en
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@nl
P2093
P2860
P356
P1476
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.8.3621
P407
P577
1995-04-11T00:00:00Z